Whole Exome Sequencing Uncovers Hidden Genetic Causes in Adults With Unexplained Liver Disease
WES identified a genetic diagnosis in nearly 1 in 4 adults with unexplained cholestatic liver disease, including genes beyond the classic PFIC spectrum.
Summary
Many adults with unexplained cholestatic liver disease — a condition involving impaired bile flow — never receive a definitive diagnosis despite extensive testing. This study applied whole exome sequencing to 21 adults with three distinct unexplained cholestatic patterns. A genetic cause was identified in about 24% of patients. Importantly, the majority of genetic diagnoses came from genes outside the traditionally tested PFIC gene panel, including ABCC2, PPOX, and APOB. This suggests that limiting genetic testing to known PFIC genes misses a significant portion of adult cases. The findings support expanding genetic testing panels for adults with unexplained cholestasis and open the door to more personalized, targeted treatment approaches for what were previously considered idiopathic liver conditions.
Detailed Summary
Cholestatic liver diseases — conditions where bile flow is impaired — affect a substantial number of adults and can cause progressive liver damage, cirrhosis, and liver failure. A meaningful proportion of these cases remain unexplained even after comprehensive clinical, biochemical, and imaging workups. Identifying an underlying genetic cause in these patients can transform clinical management, enabling precision medicine approaches and informing family screening.
This study from Italian tertiary centers enrolled 21 adults presenting with one of three unexplained cholestatic phenotypes: recurrent lithiasis (gallstone-related), unexplained intrahepatic cholestasis, and primary sclerosing cholangitis with atypical features. All patients underwent whole exome sequencing, with variants analyzed across a broad panel of cholestatic and liver disease genes — extending well beyond the genes classically associated with progressive familial intrahepatic cholestasis (PFIC).
WES yielded a definitive genetic diagnosis in 5 of 21 patients (23.8%). ABCB4 — a gene linked to low-phospholipid-associated cholelithiasis and cholestasis — was responsible in two cases. Strikingly, the remaining three diagnoses involved genes not typically included in standard PFIC testing panels: ABCC2 (associated with Dubin-Johnson syndrome), PPOX (linked to variegate porphyria), and APOB (linked to hypobetalipoproteinemia). These findings underscore that adult cholestasis has a broader and more diverse genetic architecture than previously appreciated.
The clinical implications are significant. A 24% diagnostic yield from WES in this difficult-to-diagnose population is clinically meaningful, especially considering that each diagnosis can redirect management — for example, avoiding hepatotoxic medications in porphyria, or using ursodeoxycholic acid in ABCB4-related disease. Expanding genetic panels beyond PFIC genes appears essential for adult hepatology practice.
Caveats include the small sample size of 21 patients and the single-center design, which limits generalizability. The summary is based on the abstract only, so full methodological details and subgroup analyses are unavailable. Larger prospective studies are needed to validate these findings and define the optimal gene panel for adult cholestasis workups.
Key Findings
- WES identified a genetic diagnosis in 23.8% of adults with unexplained cholestatic liver disease.
- 60% of genetic diagnoses involved genes outside the standard PFIC testing panel (ABCC2, PPOX, APOB).
- ABCB4 was the most common causative gene, implicated in 2 of 5 diagnosed cases.
- Three distinct cholestatic phenotypes were studied: recurrent lithiasis, intrahepatic cholestasis, and atypical PSC.
- Expanding WES gene panels beyond PFIC genes is essential to capture the full adult cholestasis genetic landscape.
Methodology
This was a single-center observational study enrolling 21 adults with unexplained cholestatic liver disease who underwent whole exome sequencing. Pathogenic and rare damaging variants were prioritized across a broad set of cholestatic and liver disease candidate genes, with genotype-phenotype correlations performed. The study is limited by its small and likely selected tertiary-center cohort.
Study Limitations
The study enrolled only 21 patients from a single tertiary center, making generalizability uncertain and statistical power limited. This summary is based on the abstract only; full methodology, patient characteristics, and detailed variant data were not available for review. A prospective, multicenter study with a larger cohort is needed to confirm diagnostic yield estimates.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.